The PCSK9 inhibitors alirocumab (Praluent®) and evolocumab (Repatha®) are available under the High Tech Arrangement. A Managed Access Protocol is in place for the PCSK9 inhibitors. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of alirocumab or evolocumab under the High Tech Arrangement.
The prescribing of alirocumab (Praluent®) and evolocumab (Repatha®) under the High Tech Arrangement is confined to designated clinicians who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme.
The clinician must submit an online application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
A copy of the HSE-Managed Access Protocol for PCSK9 inhibitors can be found in the Related Files section below.